Chronic Disease Management Market Regional Analysis:
North American Market Insights
North America is predicted to account for the highest chronic disease management market share of 47% over the assessed timeline. The region’s proprietorship is significantly impelled by increasing spending in healthcare in developed countries such as the U.S. and Canada. As per the American Medical Association, healthcare expenditure in the U.S. rose by 4.1% in 2022, reaching USD 4.5 trillion. This has led to an increase in access to quality medical treatments for people with chronic diseases residing across the region. Besides, the enlarging patient pool, the increasing availability of sufficient resources, and the presence of specialized training facilities are fostering a good capital influx in this landscape.
According to the CDC statistics, the number of citizens in the U.S. with a minimum of 1 chronic illness surpassed 129.0 million in 2024. Additionally, the country consists of a large obese adult population, which reached 100.0 million in 2023 (NORC at the University of Chicago). This indicates a continuously emphasizing patient pool, creating new business opportunities. This demography is further attracting global pioneers to invest and participate in the chronic disease management market. For instance, in March 2024, UTMHealthcare, in partnership with the Somml Health platform, introduced NuLink Health in the U.S., enhancing chronic disease care and cost efficiencies for medical practices.
APAC Market Insights
Asia Pacific is expected to register a remarkable CAGR in the chronic disease management market throughout the analysed timeframe. The increased rate of mortality from chronic illnesses across this region is pushing authorities in developing countries, such as Japan, Australia, China, and India, to establish a standardized and efficient system of patient care. This is garnering a great scope of doing profitable business for global leaders. Furthermore, the improving reimbursement policies are escalating accessibility in this field. For instance, in July 2025, the Government of Australia upgraded its Medicare Benefits Schedule (MBS) items, enabling multidisciplinary team care for habitats suffering from chronic conditions.
India is becoming one of the largest contributors and revenue generators in the market, owing to its large patient population, increased disposable income, and enhanced MedTech development. Additionally, the home healthcare industry in this country is gaining traction, which is poised to be valued at USD 19.9 billion by 2025, up from USD 5.4 billion in 2022 (Healthcare Federation of India). Thus, this augmenting landscape is attracting more investors and participants. On this note, in June 2023, TatvaCare launched a cutting-edge digital therapeutic application, MyTatva, for the treatment and management of chronic conditions, such as COPD and Asthma, in India.
